

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

Asian Journal of Psychiatry



journal homepage: www.elsevier.com/locate/ajp

Letter to the Editor

Finding Horcrux of psychiatric symptoms in COVID-19: Deficiencies of amino acids and vitamin D

Arundhati Mehta¹, Vivek Kumar Soni¹

Department of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, 495009 Chhattisgarh, India

Krishna Sharma

Department of Psychology, Government Bilasa Girls Post Graduate Autonomous College, Bilaspur, 495001 Chhattisgarh, India

Yashwant Kumar Ratre, Dhananjay Shukla

Department of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, 495009 Chhattisgarh, India

Alok Kumar Singh *

Department of Cardiology, Opal Hospital, Varanasi, 221006 Uttar Pradesh, India

Naveen Kumar Vishvakarma **

Department of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, 495009 Chhattisgarh, India

ARTICLE INFO

Keywords Amino Acids COVID-19 Neurotransmitters Psychiatric illness Vitamin D

Dear Editor A diverse range of psychiatric complications is involved in patients suffering from COVID-19 (Tandon, 2020). Moreover, psychiatric complications including anxious and depressive disorders are being reported even in those individuals who recovered from COVID-19 (Abrishami et al., 2020). Tandon (2020) has pressed the need for a multidisciplinary approach as a priority to combat ill-effects associated with the COVID-19 pandemic. The world has also been predicted to face a flood of psychiatric illness even in the post-pandemic era (Tandon, 2020). An intervened pyschoneuroendocrineimmune (PNEI) response governs the overall consequences of altered physiological and psychiatric presentation even in COVID-19. (Tandon, 2020; Soni et al., 2020a). Therefore the role of 'physiological spoils' as raison d'être for psychiatric sequelae of COVID-19 cannot be overlooked. Physiological offend caused by COVID-19 culminate into gastrointestinal (GI) disturbances; leading to malabsorption. COVID-19 share psychiatric symptoms with Hartnup disorder, a genetic condition with GI expression of defective amino acid transporters (Soni et al., 2020b). The dysfunctional state of angiotensin-converting enzyme-2 (ACE-2), cellular doorway of SARS-CoV-2, downregulates the expression of amino acid transporters.

** Corresponding author.

https://doi.org/10.1016/j.ajp.2020.102523 Received 1 November 2020;

Available online 25 December 2020 1876-2018/© 2020 Published by Elsevier B.V.

^{*} Corresponding author.

E-mail address: E-mail address: alok ims@rediffmail.com. naveenvishva@gmail.com.

 $^{^{1}\,}$ AM and VKS contributed equally to this article as first authors.

Hindered uptake and deficiency of amino acids contribute to multiple psychiatric consequences (Carnegie et al., 2020). Several neurotransmitters including dopamine, epinephrine, gamma-aminobutyric acid (GABA), melatonin, norepinephrine, and serotonin derive from various amino acids (glutamate, glycine, glutamate, phenylalanine, tyrosine, tryptophan, etc); and mental well being is also regulated through metabolic derivates of amino acids such as tryptophan catabolites (TRYCATs) (Soni et al., 2020b; Carnegie et al., 2020). Deficiencies of amino acids in COVID-19 are expected to modulate physiological as well as psychiatric wellness (Soni et al., 2020b).

Similarly, a significantly lower level of Vitamin D is being invariably reported in COVID-19 patients with severe symptoms (Abrishami et al., 2020). Vitamin D levels have been previously associated with better immunity and mental well being through modulated hematopoiesis and PNEI response (Sarris et al., 2015; Basheer et al., 2017). Reduced outdoor activities and sunlight exposure amid an ongoing pandemic (Tandon, 2020; Abrishami et al., 2020) contributed to a deficiency of this 'sunshine vitamin'. Moreover, a large population in developing and underdeveloped countries already face a low level of vitamin D and associated health consequences (Carnegie et al., 2020; Sarris et al., 2015). Various amino acids and vitamin D serve as precursors and regulators of mental well-being (Carnegie et al., 2020; Basheer et al., 2017). A lower vitamin D level is also associated with neuropsychiatric crises including major depressive disorders (MDD) and Autism (Sarris et al., 2015; Basheer et al., 2017). Moreover, a lower level of serum 25-hydroxyvitamin D has also been linked with psychological distress symptoms in COVID-19 (Di Nicola et al., 2020). Modulation in vitamin D level alters the level of brain serotonin, dopamine, estradiol, etc. Vitamin D stimulates vitamin D receptors (VDR) in CNS; regulates neuronal function. Moreover, proinflammatory cytokines have negative consequences on psychiatric well-being through PNEI response (Soni et al., 2020a); and vitamin D has an inhibitory effect on inflammation (Sarris et al., 2015). The anti-inflammatory effect of vitamin D has been exploited in various pathological conditions including malignancies and cardiovascular disorders. Vitamin D supplementation is expected to provide benefits in the prevention and cure of COVID-19-associated respiratory distress.

To achieve success in the prophylactic and curative treatment of COVID-19, several speculations have surfaced, however, leaving few, most of them are not supported by scientific pieces of evidence. Sahoo et al. (2020) had evaluated several such strategies expected to hold a benefit in COVID-19. Based on known scientific pieces of evidence; Vitamin D was speculated to deliver immunological benefits in COVID-19 (Sahoo et al., 2020). Immunological uphold by Vitamin D will also conjecture to improve the psychiatric well being through PNEI modulation (Tandon, 2020; Soni et al., 2020a).

Collectively, the deficiencies of amino acids and vitamin D can be hypothesized to trigger as well as sustain the psychiatric symptoms in COVID-19. Conditional amino acid supplementation improves the neuropsychiatric state of individuals. Supplementation of Vitamin D has been observed to provide benefits in anxious and depressive disorders including mood disorders and post-traumatic stress disorder (Sarris et al., 2015; Carnegie et al., 2020; Basheer et al., 2017); while few investigations report no benefit in the improvement of psychiatric symptoms (Okereke et al., 2020). Therefore a critical evaluation of the replenishment of these deficiencies for the healing of psychiatric consequences in COVID-19 is warranted. Although, supplementation of micronutrients, precursor amino acids, and vitamins, under supervised medical nutrition therapy (MNT), is speculated to provide neuropsychiatric benefits (Soni et al., 2020b; Sarris et al., 2015; Carnegie et al., 2020); it can also be expected to alleviate the psychiatric manifestations in COVID-19 patients.

Authors' Contribution

AKS and NKV conceived the idea; AM, VKS, KS, and YKR compiled the literature; VKS, KS, AM, YKR, DS, AKS, and NKV wrote the manuscript; KS, DS, AKS, and NKV reviewed the manuscript; all authors have approved the final version of the manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of Competing Interest

None.

Acknowledgment

Financial support to AM and YKR [GGU-VRET-Fellowship] and VKS [UGC-SRF] as fellowships are acknowledged. UGC-Special Assistance Program (UGC-SAP) at the Department of Biotechnology (Guru Ghasidas Vishwavidyalaya) is also acknowledged for necessary facilities in preparation of the manuscript.

References

- Abrishami, A., Dalili, N., Mohammadi Torbati, P., Asgari, R., Arab-Ahmadi, M., Behnam, B., Sanei-Taheri, M., 2020. Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study. European journal of nutrition 1–9. https://doi.org/10.1007/s00394-020-02411-0. Advance online publication.
- Basheer, S., Natarajan, A., van Amelsvoort, T., Venkataswamy, M.M., Ravi, V., Srinath, S., Girimaji, S.C., Christopher, R., 2017. Vitamin D status of children with Autism Spectrum Disorder: Case-control study from India. Asian journal of psychiatry 30, 200–201. https://doi.org/10.1016/j.ajp.2017.10.031.
- Carnegie, R., Zheng, J., Sallis, H.M., Jones, H.J., Wade, K.H., Evans, J., Zammit, S., Munafò, M.R., Martin, R.M., 2020. Mendelian randomisation for nutritional psychiatry. The lancet. Psychiatry 7 (2), 208–216. https://doi.org/10.1016/S2215-0366(19)30293-7.
- Di Nicola, M., Dattoli, L., Moccia, L., Pepe, M., Janiri, D., Fiorillo, A., Janiri, L., Sani, G., 2020. Serum 25-hydroxyvitamin D levels and psychological distress symptoms in patients with affective disorders during the COVID-19 pandemic. Psychoneuroendocrinology 122, 104869. https://doi.org/10.1016/j. psyneuen.2020.104869. Advance online publication.
- Okereke, O.I., Reynolds 3rd, C.F., Mischoulon, D., Chang, G., Vyas, C.M., Cook, N.R., Weinberg, A., Bubes, V., Copeland, T., Friedenberg, G., Lee, I.M., Buring, J.E., Manson, J.E., 2020. Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. JAMA 324 (5), 471–480. https://doi.org/ 10.1001/jama.2020.10224.
- Sahoo, S., Padhy, S.K., Ipsita, J., Mehra, A., Grover, S., 2020. Demystifying the myths about COVID-19 infection and its societal importance. Asian journal of psychiatry 54, 102244. https://doi.org/10.1016/j.ajp.2020.102244. Advance online publication.
- Sarris, J., Logan, A.C., Akbaraly, T.N., Amminger, G.P., Balanzá-Martínez, V., Freeman, M.P., Hibbeln, J., Matsuoka, Y., Mischoulon, D., Mizoue, T., Nanri, A., Nishi, D., Ramsey, D., Rucklidge, J.J., Sanchez-Villegas, A., Scholey, A., Su, K.P., Jacka, F.N., International Society for Nutritional Psychiatry Research, 2015. Nutritional medicine as mainstream in psychiatry. The lancet. Psychiatry 2 (3), 271–274. https://doi.org/10.1016/S2215-0366(14)00051-0.
- Soni, V.K., Mehta, A., Shukla, D., Kumar, S., Vishvakarma, N.K., 2020a. Fight COVID-19 depression with immunity booster: Curcumin for psychoneuroimmunomodulation. Asian journal of psychiatry 53, 102378. https://doi.org/10.1016/j. ajp.2020.102378. Advance online publication.
- Soni, V.K., Sharma, K., Mehta, A., Ratre, Y.K., Kumar, S., Shukla, D., Vishvakarma, N.K., 2020b. A physiological link for psychiatric symptoms in COVID-19: Role of amino acid deficiency. Asian Journal of Psychiatry 53, 102426. https://doi.org/10.1016/j. ajp.2020.102426.
- Tandon, R., 2020. COVID-19 and mental health: Preserving humanity, maintaining sanity, and promoting health. Asian journal of psychiatry (51), 102256. https://doi. org/10.1016/j.ajp.2020.102256.